capmatinib (Tabrecta) Report issue

Small molecule Orphan Drug FDA Approved FDA Breakthrough Therapy FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank MeSH PubChem
Back

Drug Pricing Summary

VA Big4

$119.8795 - $119.9784

VA FSS

$158.6571

Drug Product Pricing

Product $/unit Ctry. List Type
Product (units) Manufacturer
capmatinib 150 mg (TABLET) $119.9784 VA Big4
  • TABRECTA (56)
    		•  Novartis Pharmaceuticals Corporation
    capmatinib 150 mg (TABLET) $158.6571 VA FSS
  • TABRECTA (56)
    		•  Novartis Pharmaceuticals Corporation
    capmatinib 200 mg (TABLET) $119.8795 VA Big4
  • TABRECTA (56)
    		•  Novartis Pharmaceuticals Corporation
    capmatinib 200 mg (TABLET) $158.6571 VA FSS
  • TABRECTA (56)
    		•  Novartis Pharmaceuticals Corporation

    Note: This drug pricing data is preliminary, incomplete, and may contain errors.

    Feedback

    Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

    Report issue